SAS Output

13-JUL-2020 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 56 39 12 4 3 0 0 02/06/2017 92 40
            39 12 4 3 0 0      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 43 23 14 8 1 0 06/05/2018 57 23
            43 23 14 8 1 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 24 12 6 3 1 0 10/23/2017 240 100
        2 Nivolumab + Ipilimumab   69 35 17 9 2 0      
            93 47 23 12 3 0      
 
  S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Y 1 Adjuvant Arm 556 63 46 22 7 1 0 02/15/2019 309 130
        2 Neoadjuvant Pembrolizumab   64 48 23 8 4 0      
            127 94 45 15 5 0      
 
    2 Y 3 Surgery 556 112 95 44 16 2 2 02/15/2019    
            112 95 44 16 2 2      
 
    3 Y 4 Post-Surgery Pembro 556 93 88 45 17 5 0 02/15/2019    
            93 88 45 17 5 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   49 9 4 2 1 1 11/03/2015 298 129
            49 9 4 2 1 1      
 
    2 E Total Registrations   16 2 2 0 0 0 11/03/2015    
            16 2 2 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 203 80
            36 0 0 0 0 0      
 
No EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   11 10 8 2 0 0 05/01/2019 170 93
            11 10 8 2 0 0